Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology

The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edem...

Full description

Bibliographic Details
Main Authors: Vincent Berezowski, Andrew M. Fukuda, Roméo Cecchelli, Jérôme Badaut
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:International Journal of Cell Biology
Online Access:http://dx.doi.org/10.1155/2012/176287
id doaj-03f0bbd2593940a3b2dd7c37e8050406
record_format Article
spelling doaj-03f0bbd2593940a3b2dd7c37e80504062020-11-24T23:37:01ZengHindawi LimitedInternational Journal of Cell Biology1687-88761687-88842012-01-01201210.1155/2012/176287176287Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic PathophysiologyVincent Berezowski0Andrew M. Fukuda1Roméo Cecchelli2Jérôme Badaut3Université Lille Nord de France, 59000 Lille, FranceDepartments of Physiology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USAUniversité Lille Nord de France, 59000 Lille, FranceDepartments of Physiology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USAThe neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke.http://dx.doi.org/10.1155/2012/176287
collection DOAJ
language English
format Article
sources DOAJ
author Vincent Berezowski
Andrew M. Fukuda
Roméo Cecchelli
Jérôme Badaut
spellingShingle Vincent Berezowski
Andrew M. Fukuda
Roméo Cecchelli
Jérôme Badaut
Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
International Journal of Cell Biology
author_facet Vincent Berezowski
Andrew M. Fukuda
Roméo Cecchelli
Jérôme Badaut
author_sort Vincent Berezowski
title Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
title_short Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
title_full Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
title_fullStr Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
title_full_unstemmed Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
title_sort endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology
publisher Hindawi Limited
series International Journal of Cell Biology
issn 1687-8876
1687-8884
publishDate 2012-01-01
description The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke.
url http://dx.doi.org/10.1155/2012/176287
work_keys_str_mv AT vincentberezowski endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology
AT andrewmfukuda endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology
AT romeocecchelli endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology
AT jeromebadaut endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology
_version_ 1725521316524589056